Skip to content
Flyout Menu
  • About Us
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
      • Boston
      • Manchester
      • Hyderabad
      • Bidar
  • Our Capabilities
    • Discovery
      • CADD & Structural Biology
      • Compound Management
      • DMPK (Drug Metabolism & Pharmacokinetics)
      • In Vitro Biology
      • In Vivo Pharmacology
      • Integrated Drug Discovery (IDD)
      • Safety & Toxicology
      • Synthetic & Medicinal Chemistry
    • Drug Substance Development
      • Analytical Development
      • Developability & Pre-Formulation
      • Particle Science & Engineering
      • Process Development
      • Process Engineering
      • Discovery Process Chemistry
    • Drug Substance Manufacturing
      • Engineering Technologies
      • Infrastructure
      • Product Types
    • New Modalities
      • Antibody–Drug Conjugates
      • Lipids
      • Oligos
      • Peptides
    • Formulations
      • Clinical Formulation Supplies
      • New Chemical Entity (NCE) formulation development
  • Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Newsroom – Blogs
    • Newsroom – Case Studies
  • Investors
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
  • Our Capabilities
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
  • Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
  • Our Capabilities
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
  • Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    Main Menu
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
      • Boston
      • Manchester
      • Hyderabad
      • Bidar
  • Our Capabilities
    Main Menu
    • Discovery
      • Integrated Drug Discovery (IDD)
      • CADD & Structural Biology
      • Synthetic & Medicinal Chemistry
      • In Vitro Biology
      • DMPK (Drug Metabolism & Pharmacokinetics)
      • In Vivo Pharmacology
      • Safety & Toxicology
      • Compound Management
    • Drug Substance Development
      • Discovery Process Chemistry
      • Process Development
      • Analytical Development
      • Process Engineering
      • Particle Science & Engineering
      • Developability & Pre-Formulation
    • Drug Substance Manufacturing
      • Product Types
      • Infrastructure
      • Engineering Technologies
    • Formulations
      • New Chemical Entity (NCE) formulation development
      • Clinical Formulation Supplies
    • New Modalities
      • Antibody–Drug Conjugates
      • Peptides
      • Oligos
  • Sustainability
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    Main Menu
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
      • Boston
      • Manchester
      • Hyderabad
      • Bidar
  • Our Capabilities
    Main Menu
    • Discovery
      • Integrated Drug Discovery (IDD)
      • CADD & Structural Biology
      • Synthetic & Medicinal Chemistry
      • In Vitro Biology
      • DMPK (Drug Metabolism & Pharmacokinetics)
      • In Vivo Pharmacology
      • Safety & Toxicology
      • Compound Management
    • Drug Substance Development
      • Discovery Process Chemistry
      • Process Development
      • Analytical Development
      • Process Engineering
      • Particle Science & Engineering
      • Developability & Pre-Formulation
    • Drug Substance Manufacturing
      • Product Types
      • Infrastructure
      • Engineering Technologies
    • Formulations
      • New Chemical Entity (NCE) formulation development
      • Clinical Formulation Supplies
    • New Modalities
      • Antibody–Drug Conjugates
      • Peptides
      • Oligos
  • Sustainability
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us

Global Business Reports interviews Krishna Kanumuri, MD & CEO Sai Life Sciences on the company’s journey of transformation

3 Dec 2019

A recent edition of Global Business Reports (GBR) on India Pharmaceuticals 2019 features the interview with Krishna Kanumuri, MD & CEO of Sai Life Sciences. In the interview, Krishna provides a glimpse of the 20 years of the company, and how it is building itself for the future.

Here’s an excerpt from the interview:
“Sai Life Sciences is undergoing major transformation. Over a period from 2016 to 2020, our company is quadrupling in capacity. This capacity, combined with our proven track record and commitment to building long term partnerships, will no doubt make Sai Life Sciences the partner of choice for large pharma and small biotechs in bringing new medicines to life.”, says CEO Krishna Kanumuri.

Here is the link to read the full interview.

Related News

  • News

Sai Life Sciences hosts Biotech Pitch Day 2026 at Boston Site

Sai Life Sciences successfully hosted its Biotech Pitch Day 2026 at its Boston-area site on March 19, bringing together a dynamic group […]

20 Apr 2026

Sai Life Sciences Limited delivers robust performance in 9MFY26

Revenue up by 43%; EBITDA up by 79%; Net Profit up by 199% Hyderabad, February 05, 2026: Sai Life Sciences […]

6 Feb 2026

Mabtech and Sai Life Sciences Announce Strategic Collaboration to Advance Immunology Research with EYRA Platform at Sai Boston Site

Mabtech, a global life science tools company specializing in advanced immunoassays, and Sai Life Sciences, a leading integrated Contract Research, […]

28 Jan 2026
5 / 45 FirstPrevious34567Next Last

DS-7, IKP Knowledge Park,
Turkapally Village, Shameerpet Mandal,
Medchal-Malkajgiri District-500078,
Telangana, India

Company
Main Menu
  • About Us
  • Investors
  • Careers
  • Contact us
Our Capabilities
Main Menu
  • Discovery
  • Drug Substance Development
  • Drug Substance Manufacturing
  • Formulations
  • New Modalities
Knowledge Hub
Main Menu
  • News
  • Blogs
  • Case Studies
Legal
Main Menu
  • Privacy Policy
  • Cookie Policy
  • Terms & Conditions

© 2026 Sai Life Sciences All rights reserved.

Facebook-f Instagram Linkedin-in X-twitter Youtube